Monday, December 01, 2008
Correspondence: Cultural Challenges in Caring for Our Patients in Advanced Stages of Cancer
JCO.2008.19.9455v1.pdf (application/pdf Object)
Stern adherence to scientific methods cannot fully encompass the depth and breadth of our tasks in supportive, palliative, and end-of-life care.
Does Age Really Matter? Recall of Information Presented to Newly Referred Patients With Cancer -- Jansen et al. 26 (33): 5450 -- Journal of Clinical Oncology
Does Age Really Matter? Recall of Information Presented to Newly Referred Patients With Cancer -- Jansen et al. 26 (33): 5450 -- Journal of Clinical Oncology
"Conclusion: Recall is not simply a function of patient age. Age only predicts recall when controlling for amount of information presented. Both prognosis and information about prognosis are better predictors of recall than age. These results provide important insights into intervention strategies to improve information recall in patients with cancer"
GenomeWeb News: International Cancer Genome Consortium Announces Eight New Projects
GenomeWeb News: International Cancer Genome Consortium Announces Eight New Projects
International Cancer Genome Consortium Announces Eight New Projects
November 19, 2008By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The International Cancer Genome Consortium announced today that eight countries and 11 funding agencies have signed on to participate in comprehensive analyses of the genomic changes underlying eight types of cancer.
The new projects are designed to complement the Cancer Genome Atlas pilot projects on brain, lung, and ovarian cancers. The goal is to map the genetic and genomic changes occurring in different types and stages of cancer in an effort to understand disease biology and develop new preventive strategies, diagnostics, and therapies.
Each participating organization will tackle one or more types of cancer using samples collected from about 500 individuals. Data collection and analysis will be standardized and is to follow ICGC guidelines released in April. Participating countries and agencies will also use common informed consent and ethical oversight standards. The estimated cost of each project is $20 million.
The ICGC anticipates additional countries and groups joining the effort through other projects in the next decade and eventually plans to study 50 types of cancer. Overall, the ICGC expects to generate some 25,000 times more data than the Human Genome Project.
ICGC data will be made available to the research community freely and rapidly, and participants are expected to agree that they will not file patents or make intellectual property claims on ICGC project primary data.
The new ICGC projects include:
- An Australian study funded by the National Health and Medical Research Council (the tumor type to has not yet been announced)
- A Canadian study funded by the Ontario Institute for Cancer Research on pancreatic cancer
- A Chinese study funded by the Chinese Cancer Genome Consortium on stomach cancer
- French studies on alcohol-related liver cancer and HER2-positive breast cancers funded by the Institut National du Cancer
- An Indian study on oral cavity cancer funded by the Department of Biotechnology Ministry of Science and Technology
- A study of virus-related liver cancer in Japan, funded by RIKEN, the National Cancer Center, and the National Institute of Biomedical Innovation
- A Spanish study of chronic lymphocytic leukemia funded by the Spanish Ministry of Science and Innovation
- A study of several breast-cancer subtypes in the UK, funded by the Wellcome Trust and the Wellcome Trust Sanger Institute
Subscribe to:
Posts
(
Atom
)
Posts
